Genmab A/S (NASDAQ:GMAB) Sets New 12-Month Low - Time to Sell?

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock price reached a new 52-week low during trading on Tuesday . The stock traded as low as $19.27 and last traded at $19.08, with a volume of 38725 shares. The stock had previously closed at $20.80.

Analyst Ratings Changes

Several research firms have issued reports on GMAB. Sanford C. Bernstein raised Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. BMO Capital Markets reaffirmed an "outperform" rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Redburn Atlantic assumed coverage on Genmab A/S in a report on Tuesday, October 8th. They issued a "buy" rating on the stock. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $45.20.

Genmab A/S Trading Down 0.8 %

The company has a market cap of $13.00 billion, a P/E ratio of 19.07, a P/E/G ratio of 0.55 and a beta of 0.97. The company has a 50-day simple moving average of $21.04 and a 200 day simple moving average of $23.76.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The company had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same quarter in the previous year, the business earned $0.47 EPS. On average, equities analysts forecast that Genmab A/S will post 1.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after buying an additional 1,051 shares during the period. R Squared Ltd purchased a new stake in shares of Genmab A/S during the 4th quarter worth $93,000. Blue Trust Inc. boosted its position in Genmab A/S by 892.0% during the third quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock valued at $108,000 after purchasing an additional 3,880 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Genmab A/S by 43.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company's stock valued at $113,000 after purchasing an additional 1,413 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after purchasing an additional 827 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.